

CITATION REPORT

List of articles citing

The phage therapy paradigm: pr⁺-⁺porter or sur-mesure?

DOI: 10.1007/s11095-010-0313-5

Pharmaceutical Research, 2011, 28, 934-7.

Source: <https://exaly.com/paper-pdf/51280720/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
227	La phagothérapie: passé et avenir (faits nouveaux et procédure[s] pour une réhabilitation). 2011 , 26, 165-175		
226	Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. 2011 , 9, 775-85		120
225	Bacteriophages as twenty-first century antibacterial tools for food and medicine. 2011 , 90, 851-9		58
224	Phage treatment of human infections. 2011 , 1, 66-85		577
223	Effects of sequential and simultaneous applications of bacteriophages on populations of <i>Pseudomonas aeruginosa</i> in vitro and in wax moth larvae. 2012 , 78, 5646-52		92
222	Introducing yesterday's phage therapy in today's medicine. 2012 , 7, 379-390		58
221	Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications. 2012 , 13, 699-722		151
220	In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model. 2012 , 56, 949-54		27
219	Phage therapy--history from Twort and d'Herelle through Soviet experience to current approaches. 2012 , 83, 3-40		158
218	Rapid identification of international multidrug-resistant <i>Pseudomonas aeruginosa</i> clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages. 2012 , 56, 6175-80		17
217	Clinical aspects of phage therapy. 2012 , 83, 73-121		220
216	Bacteriophage based probes for pathogen detection. 2012 , 137, 3405-21		101
215	Characterization of bacteriophage β to-bp6g, a novel phage that lyses <i>Pseudomonas tolaasii</i> causing brown blotch disease in mushrooms. 2012 , 91, 514-9		9
214	New antibacterial microporous CaP materials loaded with phages for prophylactic treatment in bone surgery. 2012 , 23, 2445-52		12
213	Co-evolution with lytic phage selects for the mucoid phenotype of <i>Pseudomonas fluorescens</i> SBW25. 2012 , 6, 1148-58		70
212	Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. 2012 , 60, 161-72		55
211	Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. 2012 , 5, 575-82		65

210	Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. 2013 , 57, 5961-8	88
209	A metagenomic insight into our gut's microbiome. 2013 , 62, 146-58	234
208	Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. 2013 , 84, 578-82	84
207	Treatment, promotion, commotion: antibiotic alternatives in food-producing animals. 2013 , 21, 114-9	172
206	Key issues in phage therapy: a report of a dedicated workshop at the Viruses of Microbes II meeting. 2013 , 164, 806-10	4
205	Phage cocktails and the future of phage therapy. 2013 , 8, 769-83	484
204	Alternatives to antibiotics: a symposium on the challenges and solutions for animal production. 2013 , 14, 78-87	104
203	What are the limitations on the wider therapeutic use of phage?. 2013 , 3, e24872	64
202	Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy. 2013 , 14, 951-4	29
201	Qu'est-ce que la phagothérapie?. 2014 , N° 4, 354	
200	Enhancing and initiating phage-based therapies. 2014 , 4, e961869	10
199	Synthetic Biology and Therapies for Infectious Diseases. 2014 , 109-180	
198	Taking bacteriophage therapy seriously: a moral argument. 2014 , 2014, 621316	27
197	Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool. <i>Viruses</i> , 2014 , 6, 2551-70 6.2	63
196	Antibiotic alternatives: the substitution of antibiotics in animal husbandry?. 2014 , 5, 217	304
195	Exposure to phages has little impact on the evolution of bacterial antibiotic resistance on drug concentration gradients. 2014 , 7, 394-402	7
194	Bacteriophage T4 can produce progeny virions in extremely slowly growing Escherichia coli host: comparison of a mathematical model with the experimental data. 2014 , 351, 156-61	31
193	Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. 2014 , 20, O983-90	45

192	Microbial Biofilms. 2014 ,		6
191	Call for a dedicated European legal framework for bacteriophage therapy. 2014 , 62, 117-29		59
190	Finding alternatives to antibiotics. 2014 , 1323, 91-100		140
189	A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. 2014 , 5, 226-35		289
188	Parasite host range and the evolution of host resistance. 2015 , 28, 1119-30		7
187	Bacteriophages and phage-derived proteins--application approaches. 2015 , 22, 1757-73		110
186	Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. 2015 , 8, 525-58		48
185	On-Demand Isolation of Bacteriophages Against Drug-Resistant Bacteria for Personalized Phage Therapy. 2015 , 6, 1271		79
184	Ecology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm Bacteria. 2015 , 8, 559-89		62
183	Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. 2015 , 10, e0118557		154
182	Unexploited opportunities for phage therapy. 2015 , 6, 180		35
181	Experimental evolution and bacterial resistance: (co)evolutionary costs and trade-offs as opportunities in phage therapy research. 2015 , 5, e1050153		34
180	Bacteriophage Therapy: Advances in Formulation Strategies and Human Clinical Trials. 2015 , 2, 599-618		91
179	Coevolution with bacteriophages drives genome-wide host evolution and constrains the acquisition of abiotic-beneficial mutations. 2015 , 32, 1425-35		77
178	Quality and safety requirements for sustainable phage therapy products. <i>Pharmaceutical Research</i> , 2015 , 32, 2173-9	4-5	129
177	Antimicrobial Phages. 2015 , 567-581		1
176	Phages targeting infected tissues: novel approach to phage therapy. 2015 , 10, 199-204		35
175	Phage therapy of pulmonary infections. 2015 , 5, e1020260		62

174	Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections. 2015 , 89, 7449-56	80
173	Bacteriophage therapy: history and future prospects. 2015 , 10, 449-461	21
172	In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients. 2015 , 99, 6021-33	39
171	Bacteriophage-based Products and Techniques for Identification of Biological Pathogens. 2015 , 17-33	2
170	Set Phages to Stun: Reducing the Virulence of Staphylococcus aureus in Diabetic Foot Ulcers. 2015 , 64, 2701-3	
169	Nanotechnology to Aid Chemical and Biological Defense. 2015 ,	1
168	Modeling tailed bacteriophage adsorption: Insight into mechanisms. 2015 , 485, 355-62	38
167	The Potential Use of Bacteriophage Therapy as a Treatment Option in a Post-Antibiotic Era. 2016 , 309-328	2
166	Bacteriophages as Potential Treatment for Urinary Tract Infections. 2016 , 7, 465	54
165	Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics. 2016 , 7, 1209	94
164	GP0.4 from bacteriophage T7: in silico characterisation of its structure and interaction with E. coli FtsZ. 2016 , 9, 343	2
163	Alternatives to overcoming bacterial resistances: State-of-the-art. 2016 , 191, 51-80	147
162	Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. 2016 , 29, 188-98	55
161	Bacteriophage application to control the contaminated water with Shigella. 2016 , 6, 22636	28
160	A bacteriophage journey at the European Medicines Agency. 2016 , 363, fnv225	47
159	Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework. 2016 , 363,	9
158	Regulating phage therapy: The biological master file concept could help to overcome regulatory challenge of personalized medicines. 2017 , 18, 198-200	33
157	Phage therapy is highly effective against chronic lung infections with. 2017 , 72, 666-667	106

156	MΦage Φtrois in the human gut: interactions between host, bacteria and phages. 2017 , 15, 397-408	184
155	Phage therapy for the treatment of human intestinal bacterial infections: soon to be a reality?. 2017 , 11, 785-788	17
154	Embracing the enemy: the diversification of microbial gene repertoires by phage-mediated horizontal gene transfer. 2017 , 38, 66-73	133
153	Bacteriophage and Antimicrobial Resistance. 2017 , 19-57	3
152	Phages Against Infectious Diseases. 2017 , 269-294	3
151	Bioprospecting. 2017 ,	3
150	The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in <i>Pseudomonas aeruginosa</i> -infected airways. 2017 , 16, 663-670	31
149	Bacteriocins and bacteriophage; a narrow-minded approach to food and gut microbiology. 2017 , 41, S129-S153	47
148	<i>Pseudomonas</i> predators: understanding and exploiting phage-host interactions. 2017 , 15, 517-530	94
147	Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections. <i>Expert Opinion on Drug Delivery</i> , 2017 , 14, 959-972	8 28
146	Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. 2017 , 17, 90	82
145	Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?. 2018 , 102, 2563-2581	102
144	Design of a Broad-Range Bacteriophage Cocktail That Reduces <i>Pseudomonas aeruginosa</i> Biofilms and Treats Acute Infections in Two Animal Models. 2018 , 62,	108
143	Bacteriophage Clinical Use as Antibacterial "Drugs": Utility and Precedent. 2017 , 5,	34
142	Bacteriophage Therapy. 2018 ,	4
141	Bacteriophage Production in Compliance with Regulatory Requirements. 2018 , 1693, 233-252	21
140	Guidelines for Bacteriophage Product Certification. 2018 , 1693, 253-268	17
139	An ecosystem framework for understanding and treating disease. 2018 , 2018, 270-286	8

138	Characterization of vB_Kpn_F48, a Newly Discovered Lytic Bacteriophage for <i>Klebsiella pneumoniae</i> of Sequence Type 101. <i>Viruses</i> , 2018 , 10,	6.2	21
137	Bacteriophage Clinical Use as Antibacterial Drugs—Utility and Precedent. 2018 , 417-451		
136	[Antibacterial applications of bacteriophages]. 2020 , 24, 23-36		1
135	Applications of Bacteriophages in the Treatment of Localized Infections in Humans. 2018 , 9, 1696		64
134	Antimicrobial Resistance: Its Surveillance, Impact, and Alternative Management Strategies in Dairy Animals. 2017 , 4, 237		95
133	Design and Evaluation of Phage Cocktails Against. 2018 , 9, 1476		30
132	Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against in Cystic Fibrosis. An Argumentative Review. 2018 , 9, 775		27
131	The Magistral Phage. <i>Viruses</i> , 2018 , 10,	6.2	143
130	Criteria for Selecting Suitable Infectious Diseases for Phage Therapy. <i>Viruses</i> , 2018 , 10,	6.2	34
129	Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy. <i>Viruses</i> , 2018 , 10,	6.2	179
128	Chestnut Honey and Bacteriophage Application to Control Biofilms: Evaluation in a Wound Model. 2018 , 9, 1725		36
127	Isolation and Characterization of Specific Phages to Prepare a Cocktail Preventing <i>sp. Va-F3</i> Infections in Shrimp (). 2019 , 10, 2337		18
126	Phage Therapy: A Practical Approach. 2019 ,		9
125	Constructing and Characterizing Bacteriophage Libraries for Phage Therapy of Human Infections. 2019 , 10, 2537		27
124	Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies. 2019 , 83,		59
123	Mini-review: efficacy of lytic bacteriophages on multispecies biofilms. 2019 , 35, 472-481		19
122	Phage Therapy Regulation: From Night to Dawn. <i>Viruses</i> , 2019 , 11,	6.2	49
121	Bacteriophages engineered to display foreign peptides may become short-circulating phages. 2019 , 12, 730-741		23

120	Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. 2019 , 39, 2000-2025		100
119	Towards Inhaled Phage Therapy in Western Europe. <i>Viruses</i> , 2019 , 11,	6.2	22
118	Protection of Phage Applications in Crop Production: A Patent Landscape. <i>Viruses</i> , 2019 , 11,	6.2	9
117	Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins. 2019 , 47, 449-460		25
116	Clinical application of bacteriophages in Europe. 2019 , 40, 8		10
115	Pharmacological and Immunological Aspects of Phage Therapy. 2019 , 1, 34-42		11
114	Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections. <i>Viruses</i> , 2018 , 11,	6.2	58
113	Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against <i>Staphylococcus aureus</i> biofilms in vitro. 2019 , 14, e0209390		66
112	Complete genome sequences of <i>Aeromonas</i> and <i>Pseudomonas</i> phages as a supportive tool for development of antibacterial treatment in aquaculture. 2019 , 16, 4		15
111	A century of bacteriophage research and applications: impacts on biotechnology, health, ecology and the economy!. 2019 , 94, 323-342		10
110	The Virulence Index: A Metric for Quantitative Analysis of Phage Virulence. 2020 , 1, 27-36		18
109	Managing urinary tract infections through phage therapy: a novel approach. 2020 , 65, 217-231		19
108	Drying of Vaccines and Biomolecules. 2020 , 1-23		6
107	The Unique Role That WHO Could Play in Implementing Phage Therapy to Combat the Global Antibiotic Resistance Crisis. 2020 , 11, 1982		4
106	Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?. 2020 , 42, 1659-1680		44
105	Genome-wide screens reveal <i>Escherichia coli</i> genes required for growth of T1-like phage LL5 and V5-like phage LL12. 2020 , 10, 8058		9
104	Current challenges and future opportunities of phage therapy. 2020 , 44, 684-700		39
103	Bacteriophages, a New Therapeutic Solution for Inhibiting Multidrug-Resistant Bacteria Causing Wound Infection: Lesson from Animal Models and Clinical Trials. 2020 , 14, 1867-1883		16

102	Phage Therapy as a Novel Strategy in the Treatment of Urinary Tract Infections Caused by. 2020 , 9,	15
101	Phage Therapy in the Year 2035. 2020 , 11, 1171	24
100	Bacteriophage Therapy: Developments and Directions. 2020 , 9,	31
99	Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus. 2020 , 20, 204	10
98	Bacteriophages: cancer diagnosis, treatment, and future prospects. 2021 , 51, 23-34	2
97	Introduction to Bacteriophages. 2021 , 3-16	
96	Selection of Disease Targets for Phage Therapy. 2021 , 1129-1150	
95	Phage-Encoded Endolysins. 2021 , 10,	27
94	Bacteriophage Pharmacology and Immunology. 2021 , 295-339	0
93	Potential of Therapeutic Bacteriophages in Nosocomial Infection Management. 2021 , 12, 638094	3
92	Clinical Phage Microbiology: A suggested in-vitro framework for phage therapy.	0
91	Potential for bacteriophage therapy for pneumonia with influenza A coinfection. 2021 , 16, 135-142	1
90	Strategy for mass production of lytic Staphylococcus aureus bacteriophage pSa-3: contribution of multiplicity of infection and response surface methodology. 2021 , 20, 56	5
89	Wastewater as a fertility source for novel bacteriophages against multi-drug resistant bacteria. 2021 , 28, 4358-4364	5
88	Phages Are Naturally Bred and Have a Vastly Improved Host Range in over Wild Type Phages. 2021 , 14,	8
87	Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future. 2021 , 35, 255-280	10
86	Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium. <i>Viruses</i> , 2021 , 13,	6.2 7
85	Overcoming the growth-infectivity trade-off in a bacteriophage slows bacterial resistance evolution. 2021 , 14, 2055-2063	6

84	Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments. 2021 , 12, 692614	8
83	Evolutionary biology and development model of medicines: A necessary 'pas de deux' for future successful bacteriophage therapy. 2021 ,	2
82	Recent progress towards the implementation of phage therapy in Western medicine. 2021 ,	11
81	The Use of Bacteriophages and Immunological Monitoring for the Treatment of a Case of Chronic Septicemic Cutaneous Ulcerative Disease in a Loggerhead Sea Turtle <i>Caretta caretta</i> . 2021 , 33, 139-154	2
80	infection: from standard to alternative treatment strategies. 2021 , 1-21	3
79	Clinical Phage Microbiology: a suggested framework and recommendations for the in-vitro matching steps of phage therapy.. 2021 , 2, e555-e563	7
78	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. 2021 , 921-951	1
77	Isolation and characterization of bacteriophages from the human skin microbiome that infect <i>Staphylococcus epidermidis</i> . 2021 , 2,	2
76	The Selection and Optimization of Phage Hosts. 2021 , 689-698	0
75	Regulatory Aspects of the Therapeutic Use of Bacteriophages: Europe. 2021 , 1165-1177	1
74	Pulling the Brakes on Fast and Furious Multiple Drug-Resistant (MDR) Bacteria. 2021 , 22,	8
73	Bacteriophage attack as an anti-biofilm strategy. 2014 , 1147, 277-85	12
72	Production of Phage Therapeutics and Formulations: Innovative Approaches. 2019 , 3-41	1
71	Developing Phages into Medicines for Europe. 2019 , 351-361	1
70	How to Achieve a Good Phage Therapy Clinical Trial?. 2019 , 147-168	3
69	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. 2018 , 1-31	8
68	Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. 2020 , 6,	49
67	Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against <i>Staphylococcus aureus</i> biofilms in vitro.	2

66	The susceptibility of <i>Pseudomonas aeruginosa</i> strains from cystic fibrosis patients to bacteriophages. 2013 , 8, e60575	54
65	The Janus-Face of Bacteriophages across Human Body Habitats. 2016 , 12, e1005634	16
64	Effectiveness of Bacteriophage Therapy in Field Conditions and Possible Future Applications. 2020 , 21, 364-373	1
63	Antibiotics and Phage Sensitivity as Interventions for Controlling <i>Escherichia coli</i> Isolated from Clinical Specimens. 2017 , 11, 1749-1755	1
62	Comparison between American and European legislation in the therapeutical and alimentary bacteriophage usage. 2020 , 91, e2020023	2
61	Exploring the risks of phage application in the environment. 2013 , 4, 358	74
60	Characterization of Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Phages From Sewage at a Tertiary Pediatric Hospital. 2016 , 5,	4
59	Phage Therapy Related Microbial Succession Associated with Successful Clinical Outcome for a Recurrent Urinary Tract Infection. <i>Viruses</i> , 2021 , 13,	6.2 3
58	Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth. 2021 , 14,	16
57	Importance of Bacteriophage in Combating Hospital-Acquired Infection (HAI). 2014 , 05, 1192-1201	
56	Bacteriophage Pharmacology and Immunology. 2018 , 1-45	0
55	Introduction. 2018 , 1-14	
54	THE POSSIBILITIES OF USING PHAGE THERAPY IN DENTISTRY. 2018 , 22, 107-110	
53	Protection of phage applications in crop production: a patent landscape.	
52	The Virulence Index: A Metric for Quantitative Analysis of Phage Virulence.	
51	The Selection and Optimization of Phage Hosts. 2020 , 1-10	
50	Evaluation of gel-forming eye drop containing bacteriophage against keratoconjunctivitis. 2021 , 11, 281-287	0
49	Introduction to Bacteriophages. 2020 , 1-14	

48	Selection of Disease Targets for Phage Therapy. 2020 , 1-22	
47	Regulatory Aspects of the Therapeutic Use of Bacteriophages: Europe. 2020 , 1-13	
46	Phage Therapy in Cystic Fibrosis. Challenges and Perspectives. 2020 , 403-461	
45	[A review of the regulatory framework for personalized bacteriophages registration]. 2020 , 65, 259-266	1
44	Experimental phage therapy of burn wound infection: difficult first steps. 2014 , 4, 66-73	100
43	[Not Available]. 2015 , 28, 94-104	2
42	Phage Therapy: Future Inquiries. 2013 , 1, 24-35	5
41	Bacteriophages and their potential for treatment of gastrointestinal diseases. 2021 ,	1
40	Renaissance for Phage-Based Bacterial Control. 2021 ,	1
39	Phage Therapy. 2021 , 8, 4	
38	Practical Assessment of an Interdisciplinary Bacteriophage Delivery Pipeline for Personalized Therapy of Gram-Negative Bacterial Infections.. 2022 , 15,	3
37	Systematic analysis of putative phage-phage interactions on minimum-sized phage cocktails.. 2022 , 12, 2458	2
36	Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review.. 2022 ,	18
35	Presentation_1.PDF. 2018 ,	
34	Data_Sheet_1.docx. 2018 ,	
33	Data_Sheet_2.docx. 2018 ,	
32	Table_1.docx. 2018 ,	
31	Table_2.docx. 2018 ,	

30 Table_3.docx. **2018,**

29 Table_4.docx. **2018,**

28 Data_Sheet_1.docx. **2018,**

27 Data_Sheet_1.PDF. **2019,**

26 Image_1.TIF. **2019,**

25 Image_2.TIF. **2019,**

24 Image_3.TIF. **2019,**

23 Image_4.TIF. **2019,**

22 Image_5.TIF. **2019,**

21 PhREEPred: Phage Resistance Emergence Prediction web to foresee encapsulated bacterial escape from phage cocktail treatment. *Journal of Molecular Biology*, **2022**, 167670 6.5

20 Bacteriophage: A potential biocontrol agent. **2022**, 163-174

19 Phage in cancer treatment [Biology of therapeutic phage and screening of tumor targeting peptide. *Expert Opinion on Drug Delivery*, 8 1

18 In Vitro Techniques and Measurements of Phage Characteristics That Are Important for Phage Therapy Success. *Viruses*, **2022**, 14, 1490 6.2 2

17 Determination of phage susceptibility as a clinical diagnostic tool: A routine perspective. 12, 2

16 Emergence and spread of antibiotic-resistant foodborne pathogens from farm to table. 2

15 Phage Therapy: A Different Approach to Fight Bacterial Infections. Volume 16, 173-186 0

14 In vitro and in vivo evaluation of the biofilm-degrading Pseudomonas phage Motto, as a candidate for phage therapy. 0

13 Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans. **2022**, 7, 1-45 1

- 12 Bacteriophages as Biocontrol Agents in Livestock Food Production. **2022**, 10, 2126 ○
- 11 Effective Therapeutic Options for Melioidosis: Antibiotics versus Phage Therapy. **2023**, 12, 11 ○
- 10 The dynamic interplay of bacteriophage, bacteria and the mammalian host during phage therapy. **2023**, 106004 ○
- 9 Advances in the field of phage-based therapy with special emphasis on computational resources. **2023**, 24, ○
- 8 Characteristic aspects of marketing authorisation and quality assurance of bacteriophage medicinal products in the Russian Federation. ○
- 7 Evaluation of the Antimicrobial Potential and Characterization of Novel T7-Like Erwinia Bacteriophages. **2023**, 12, 180 ○
- 6 Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections. **2023**, 12, 286 1
- 5 Development and Evaluation of Bacteriophage Cocktail to Eradicate Biofilms Formed by an Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa. **2023**, 15, 427 ○
- 4 Phage cocktails: An emerging approach for the control of bacterial infection with major emphasis on foodborne pathogens. 1-29 ○
- 3 Phage Therapy Administration Route, Regimen, and Need for Supplementary Antibiotics in Patients with Chronic Suppurative Lung Disease. **2023**, 4, 4-10 ○
- 2 Optimizing Protein Production in Therapeutic Phages against a Bacterial Pathogen, Mycobacterium abscessus. **2023**, 2, 189-209 ○
- 1 Host-phage interactions and modeling for therapy. **2023**, ○